You are here

Nicotine e-cigarettes: Information for prescribers

4 May 2021

This page provides an overview of how medical practitioners can prescribe nicotine e-cigarettes and e-cigarette fluids for their patients where appropriate. It also outlines the circumstances where other health practitioners, such as nurse practitioners, can prescribe these products.

Nicotine e-cigarettes require a prescription

Electronic cigarettes, also referred to as e-cigarettes, electronic nicotine delivery systems (ENDS) or e-cigs, are products that heat a liquid ('juice') to make vapour for inhalation ('vaping').

From 1 October 2021, consumers will need a valid prescription from an Australian-registered medical practitioner to legally import nicotine e-cigarettes and liquid nicotine in Australia. This aligns with current domestic restrictions under State and Territory laws that prohibit the supply of nicotine containing e-cigarettes in Australia without a valid medical prescription.

This measure is designed to prevent the use of such products by non-smokers, particularly youth and young adults. It will provide an opportunity for current smokers to receive appropriate advice from their healthcare practitioner on the use of, and risks associated with, these products.

Certain other novel nicotine delivery products will also require a prescription, including heat-not burn tobacco.

Nicotine replacement therapies (including sprays, patches, lozenges and chews) that do not require a prescription will continue to be available from pharmacies and some retail outlets.

Nicotine e-cigarettes are 'unapproved' products

Generally, therapeutic goods (such as medicines, medical devices and biologicals) must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into, supplied in, or exported from Australia.

There are various smoking cessation aids included in the ARTG, including over-the-counter nicotine replacement therapies (including sprays, patches, lozenges and chews) and prescription medicines. There are also non-pharmaceutical approaches to smoking cessation.

There are currently no TGA approved nicotine e-cigarettes included in ARTG. Medicines not included in the ARTG are known as ‘unapproved’ medicines. There are established pathways for legal access to unapproved nicotine e-cigarettes, with a valid prescription.

Determine if nicotine e-cigarettes are suitable

The Royal Australian College of General Practitioners (RACGP) has published the second edition of Supporting smoking cessation: A guide for health professionals.

These guidelines stipulate that nicotine containing e-cigarettes are not first line treatment for smoking cessation. However, for people who have tried to achieve smoking cessation with approved pharmacotherapies but failed, and who are still motivated to quit smoking and have discussed e-cigarette use with their healthcare practitioner, nicotine containing e-cigarettes may be a reasonable intervention to recommend.

In the coming months, the TGA will publish further information resources to assist in determining if nicotine e-cigarettes are appropriate to assist with smoking cessation in your patient.

Use an established access pathway

If you determine that an unapproved nicotine e-cigarette product is clinically suitable for a patient, there are three pathways for medical practitioners to access the product:

  • Authorised Prescriber scheme
  • Special Access Scheme (SAS)
  • Personal Importation Scheme

If a patient intends to fill their prescription at an Australian (physical or on-line) pharmacy, you will need to apply to the TGA for access to the product through the Authorised Prescriber Scheme (medical practitioners only) or the Special Access Scheme Category B before you provide a prescription.

Depending on state or territory restrictions, other prescribing health practitioners may be able to apply under the SAS. However, they would need to demonstrate they have the required qualifications and expertise in the use of the product.

A flow chart outlining the steps leading to dispensing the prescription is set out below.

flowchart illustrating the steps for dispensing prescription e-cigarette nicotine

Personal Importation Scheme

The Personal Importation Scheme allows Australian residents or visitors to import certain medicines from overseas for their own personal use or the use of an immediate family member, subject to conditions.

A valid prescription from an Australian-registered medical practitioner is required to import prescription only medications, including nicotine e-cigarettes.

Any medical practitioner who considers it appropriate for their patient to use nicotine e-cigarettes for smoking cessation can prescribe nicotine e-cigarettes for personal importation. Medical practitioners do not need TGA approval to prescribe nicotine e-cigarettes for their patient when they access them through the personal importation scheme.

Individuals may import up to a three month supply of medicines per import (based on the maximum daily dose recommended by the manufacturer), but not exceed 15 months' supply in a 12-month period. They must arrange for a copy (scan or photocopy) of their prescription to be enclosed with the package the product is sent in. Australian Border Force (ABF) officials can stop the import at the Australian border if there is no prescription is enclosed in the package, and will refer the import to the TGA for assessment. If a copy of the prescription is not provided, the TGA can request that the ABF forfeit (destroy) the goods. Individuals may also face penalties for importing a prescription medicine without legal authority.

If a patient needs to import more than a three month supply in a single import, you will need to apply for access to the product through the Authorised Prescriber Scheme or Special Access Scheme before providing the prescription.

Authorised Prescriber scheme

A medical practitioner may be granted authority to become an 'Authorised Prescriber' of a specified 'unapproved' therapeutic good (or class of unapproved therapeutic goods) to a class of patients with a particular medical condition. Recent changes to the Authorised Prescriber Scheme mean that medical practitioners may apply for Authorised Prescriber approval to prescribe nicotine e-cigarettes as an aid to stop smoking without the need for ethics committee approval.

Once a doctor becomes an Authorised Prescriber, they do not need to notify the TGA each time they prescribe the unapproved product during the period of approval. However, they must report to the TGA the number of patients treated every six months. For the five year duration of the approval, no further applications or permissions are required.

You can apply to become an Authorised Prescriber of nicotine, using the SAS & Authorised Prescriber Online System or downloadable forms. A simplified nicotine-specific online form is available on the Authorised Prescriber dashboard of the SAS & Authorised Prescriber Online System. Following registration, medical practitioners can select the "New Nicotine AP application" button and the required form fields will be pre-filled ready for submission.

SAS & Authorised Prescriber Online System

For instructions, refer to the Authorised Prescriber user guidance: Special Access Scheme & Authorised Prescriber Scheme Online System

For faster processing, the SAS and Authorised Prescriber Online System is recommended. In exceptional circumstances, such as where the medical practitioner does not have access to the SAS & Authorised Prescriber Online System or there are technical issues, a downloadable nicotine-specific application form is available below:

For more information, refer to the Authorised Prescriber webpage.

Special Access Scheme (SAS)

The SAS provides for the import and supply of an unapproved therapeutic good to a single patient on a case-by-case basis.

For more information about SAS and how to submit an application, refer to the Special Access Scheme webpage. The SAS Online System is the preferred method of submission to reduce processing times for applicants.

For more information about the SAS and how to submit an application, refer to the Special Access Scheme webpage. The SAS and Authorised Prescriber Online System is the preferred method of submission to reduce processing times for applicants.

Reporting problems

We strongly encourage consumers and health professionals to report any suspected adverse events involving e-cigarettes.

The TGA has an important role in monitoring the safety of 'unapproved' medicines. Reporting adverse events helps us to build a profile of the safety of a medicine. Significant safety concerns are investigated as part of ensuring product safety in the Australian community.